Neoclassic Drug Discovery: The Case for Lead Generation Using Phenotypic and Functional Approaches
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lee, 2012, Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy, J. Med. Chem., 55, 4527, 10.1021/jm201649s
Sams-Dodd, 2013, Is Poor Research the Cause of the Declining Productivity of the Pharmaceutical Industry? An Industry in Need of a Paradigm Shift, Drug Discov. Today, 18, 211, 10.1016/j.drudis.2012.10.010
Swinney, 2013, The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines, J. Biomol. Screen., 18, 1186, 10.1177/1087057113501199
Sams-Dodd, 2005, Target-Based Drug Discovery: Is Something Wrong?, Drug Discov. Today, 10, 139, 10.1016/S1359-6446(04)03316-1
Munos, 2009, Lessons from 60 Years of Pharmaceutical Innovation, Nat. Rev. Drug Discov., 8, 959, 10.1038/nrd2961
Munos, B. A Forensic Analysis of Drug Targets from 2000 through 2012. Clin. Pharmacol. Ther., in press.
Goh, 2007, The Human Disease Network, Proc. Natl. Acad. Sci. U. S. A., 104, 8685, 10.1073/pnas.0701361104
Mestres, 2009, The Topology of Drug-Target Interaction Networks: Implicit Dependence on Drug Properties and Target Families, Mol. BioSystems, 5, 1051, 10.1039/b905821b
Adams, 1991, Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project, Science, 252, 1651, 10.1126/science.2047873
Lander, 2001, Initial Sequencing and Analysis of the Human Genome, Nature, 409, 860, 10.1038/35057062
Begley, 2012, Drug Development: Raise Standards for Preclinical Cancer Research, Nature, 483, 531, 10.1038/483531a
Prinz, 2011, Believe It or Not: How Much Can We Rely on Published Data on Potential Drug Targets?, Nat. Rev. Drug Discov., 10, 712, 10.1038/nrd3439-c1
Paul, 2010, How to Improve R&D Productivity: The Pharmaceutical Industry’s Grand Challenge, Nat. Rev. Drug Discov., 9, 203, 10.1038/nrd3078
Booth, B. Cancer Drug Targets: The March of the Lemmings. Forbes. 2012. http://www.forbes.com/sites/brucebooth/2012/06/07/cancer-drug-targets-the-march-of-the-lemmings/2/
Edwards, 2009, Open Access Chemical and Clinical Probes to Support Drug Discovery, Nat. Chem. Biol., 5, 436, 10.1038/nchembio0709-436
Belda, 2012, Small Molecule Inhibitors of the Hepatitis C Virus–Encoded NS5A Protein, Virus Res., 170, 1, 10.1016/j.virusres.2012.09.007
Lee, 1994, A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis, Nature, 372, 739, 10.1038/372739a0
Pruss, 2011, Developments in the Discovery of Drugs for Spinal Muscular Atrophy: Successful Beginnings and Future Prospects, Expert Opin. Drug Discov., 6, 827, 10.1517/17460441.2011.586692
Young, 2013, Perspective on the Discovery and Scientific Impact of p38 MAP Kinase, J. Biomol. Screen., 18, 1156, 10.1177/1087057113497401
Ohlstein, 2000, Drug Discovery in the Next Millennium, Annu. Rev. Pharmacol. Toxicol., 40, 177, 10.1146/annurev.pharmtox.40.1.177
Barabasi, 2004, Network Biology: Understanding the Cell’s Functional Organization, Nat. Rev. Genet., 5, 101, 10.1038/nrg1272
Morphy, 2004, From Magic Bullets to Designed Multiple Ligands, Drug Discov. Today, 9, 641, 10.1016/S1359-6446(04)03163-0
Morphy, 2009, Designing Multiple Ligands—Medicinal Chemistry Strategies and Challenges, Curr. Pharm. Design, 15, 587, 10.2174/138161209787315594
Keith, 2005, Multicomponent Therapeutics for Networked Systems, Nat. Rev. Drug Discov., 4, 71, 10.1038/nrd1609
Chen, 2009, A Small Molecule That Directs Differentiation of Human ESCs into the Pancreatic Lineage, Nat. Chem. Biol., 5, 258, 10.1038/nchembio.154
Chen, 2006, Self-Renewal of Embryonic Stem Cells by a Small Molecule, Proc. Natl. Acad. Sci. U. S. A., 103, 17266, 10.1073/pnas.0608156103
Chen, 2004, Dedifferentiation of Lineage-Committed Cells by a Small Molecule, J. Am Chem. Soc., 126, 410, 10.1021/ja037390k
Lairson, 2013, Small Molecule–Based Approaches to Adult Stem Cell Therapies, Annu. Rev. Pharmacol. Toxicol., 53, 107, 10.1146/annurev-pharmtox-011112-140300
Mayer, 1999, Small Molecule Inhibitor of Mitotic Spindle Bipolarity Identified in a Phenotype-Based Screen, Science, 286, 971, 10.1126/science.286.5441.971
Quintavalle, 2011, A Cell-Based High-Content Screening Assay Reveals Activators and Inhibitors of Cancer Cell Invasion, Sci. Signal, 4, ra49, 10.1126/scisignal.2002032
Shen, 2013, Small-Molecule Inducer of Beta Cell Proliferation Identified by High-Throughput Screening, J. Am. Chem. Soc., 135, 1669, 10.1021/ja309304m
Xu, 2013, Concise Review: Chemical Approaches for Modulating Lineage-Specific Stem Cells and Progenitors, Stem Cells Transl. Med., 2, 355, 10.5966/sctm.2012-0172
Yarrow, 2005, Screening for Cell Migration Inhibitors via Automated Microscopy Reveals a Rho-Kinase Inhibitor, Chem. Biol., 12, 385, 10.1016/j.chembiol.2005.01.015
Phenotypic Drug Discovery Special Interest Group. http://www.linkedin.com/groups?gid=4443471&trk=myg_ugrp_ovr
Lumpkin, M., Woodcock, J., Zoon, K. Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products. 2005. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071597.pdf
Zheng, W., Thorne, N., McKew, J.C. Phenotypic Screens as a Renewed Approach for Drug Discovery. Drug Discov. Today, in press.
Miller, 2013, Biguanides Suppress Hepatic Glucagon Signalling by Decreasing Production of Cyclic AMP, Nature, 494, 256, 10.1038/nature11808
Terstappen, 2007, Target Deconvolution Strategies in Drug Discovery, Nat. Rev. Drug Discov., 6, 891, 10.1038/nrd2410
Knight, 2010, Targeting the Cancer Kinome through Polypharmacology, Nat. Rev., 10, 130, 10.1038/nrc2787
Hart, 2005, Finding the Target after Screening the Phenotype, Drug Discov. Today, 10, 513, 10.1016/S1359-6446(05)03415-X
Iversen, 2004, HTS Assay Validation
Low, 2008, Prioritizing Hits from Phenotypic High-Content Screens, Curr. Opin. Drug Discov. Dev., 11, 338
Okada, 2000, X-Ray Diffraction Analysis of Three-Dimensional Crystals of Bovine Rhodopsin Obtained from Mixed Micelles, J. Struct. Biol., 130, 73, 10.1006/jsbi.1999.4209
Cherezov, 2007, High-Resolution Crystal Structure of an Engineered Human Beta2-Adrenergic G Protein–Coupled Receptor, Science, 318, 1258, 10.1126/science.1150577
Rosenbaum, 2007, GPCR Engineering Yields High-Resolution Structural Insights into Beta2-Adrenergic Receptor Function, Science, 318, 1266, 10.1126/science.1150609
Burdine, 2004, Target Identification in Chemical Genetics: The (Often) Missing Link, Chem. Biol., 11, 593, 10.1016/j.chembiol.2004.05.001
Cong, 2012, Chemical Genetics-Based Target Identification in Drug Discovery, Annu. Rev. Pharmacol. Toxicol., 52, 57, 10.1146/annurev-pharmtox-010611-134639
Ong, 2009, Identifying the Proteins to Which Small-Molecule Probes and Drugs Bind in Cells, Proc. Natl. Acad. Sci. U. S. A., 106, 4617, 10.1073/pnas.0900191106
Schenone, 2013, Target Identification and Mechanism of Action in Chemical Biology and Drug Discovery, Nat. Chem. Biol., 9, 232, 10.1038/nchembio.1199
Bantscheff, 2012, Chemoproteomic Approaches to Drug Target Identification and Drug Profiling, Bioorg. Med. Chem., 20, 1973, 10.1016/j.bmc.2011.11.003
Schulz, 2012, Phenotype-Based High-Content Chemical Library Screening Identifies Statins as Inhibitors of In Vivo Lymphangiogenesis, Proc. Natl. Acad. Sci. U. S. A., 109, E2665, 10.1073/pnas.1206036109
Castoreno, 2010, Small Molecules Discovered in a Pathway Screen Target the Rho Pathway in Cytokinesis, Nat. Chem. Biol., 6, 457, 10.1038/nchembio.363
Chan, 2012, Target Identification by Chromatographic Co-elution: Monitoring of Drug-Protein Interactions without Immobilization or Chemical Derivatization, Mol. Cell. Proteomics, 11, 10.1074/mcp.M111.016642
Wobbe, R. Target Finding after PDD. In Phenotypic Drug Discovery SIG. 2012. http://www.linkedin.com/groupItem?view=&gid=4443471&type=member&item=122917022&qid=0fb2239e-4f14-4a9a-a18c-9b537dc2d664&trk=group_items_see_more-0-b-cmr
Braun, 2009, An Experimentally Derived Confidence Score for Binary Protein-Protein Interactions, Nat. Methods, 6, 91, 10.1038/nmeth.1281
Schulze, 2013, What Matters Most in Commercial Success: First-in-Class or Best-in-Class?, Nat. Rev. Drug Discov., 12, 419, 10.1038/nrd4035
Hu, J., Rho, H. S., Newman, R. H., et al. Global Analysis of Phosphorylation Networks in Humans. Biochim. Biophys. Acta 2013, in press.
Morphy, 2005, Designed Multiple Ligands: An Emerging Drug Discovery Paradigm, J. Med. Chem., 48, 6523, 10.1021/jm058225d
Morphy, 2006, The Physicochemical Challenges of Designing Multiple Ligands, J. Med. Chem., 49, 4961, 10.1021/jm0603015
Kell, 2004, Here Is the Evidence, Now What Is the Hypothesis? The Complementary Roles of Inductive and Hypothesis-Driven Science in the Post-Genomic Era, BioEssays, 26, 99, 10.1002/bies.10385
Patel, 2013, Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development, J. Biomol. Screen., 18, 1164, 10.1177/1087057113505906
Zhang, M. Phenotypic Screening Targeting Neurodegenerative Diseases. J. Biomol. Screen., in press.
Figuera-Losada, M. Inhibition of Microglia Activation as a Phenotypic Screen for Multiple Targets in Drug Discovery. J. Biomol. Screen., in press.
Harpreet, S. A Screening Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia. J. Biomol. Screen., in press.
Rong, L. A Comparative High Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses J. Biomol. Screen., in press.
Smith, E. HIV Cell Fusion Assay: Phenotypic Screening Tool for the Identification of HIV Entry Inhibitors via CXCR4. J. Biomol. Screen., in press.
Carlson, 2013, Phenotypic Screening with Human Cardiomyocytes: An HTS-Compatible Assay for Interrogating Cardiac Hypertrophy, J. Biomol. Screen., 18, 1203, 10.1177/1087057113500812
Li, H. Identification of γ-Globin Inducers in a Phenotypic Screening Assay Using Human Bone Marrow Differentiated Erythroid Progenitor Cells. J. Biomol. Screen., in press.
Malany, M. Identification of Inhibitors of Triacylglyceride Accumulation in Muscle Cells: Comparison of uHTS Results from 1536-Well Plate-Based and High Content Platforms J. Biomol. Screen., in press.
Soloveva, V. Antiobesity Phenotypic Screening Looking to Increase Ob-R Cell Surface Expression. J. Biomol. Screen., in press.
Honarnejad, K. Development and Implementation of a High-throughput FRET-based Calcium Imaging Assay for Alzheimer Disease Phenotypic Drug Screening. J. Biomol. Screen., in press.
Malik, N. Functional Screening Assays with Neurons and Astrocytes Generated from Pluripotent Stem Cell–Derived Neural Stem Cells. J. Biomol. Screen., in press.
Glicksman, M. Development of a High-Content Phenotypic Screen for Novel Compounds That Inhibit TDP-43–Induced Cellular Aggregation J. Biomol. Screen., in press.
Horman, S. A Novel High-Throughput Co-culture 3D Colony Formation Assay for the Identification of Tumor-Specific Chemotherapeutics. J. Biomol. Screen., in press.
Isherwood, 2013, High-Content Analysis to Leverage a Robust Phenotypic Profiling Approach to Vascular Modulation, J. Biomol. Screen., 18, 1246, 10.1177/1087057113499775
Kelm, J. Automation-Compatible SiRNA Knock-Down Studies in Multicell-Type 3D Tumor Microtissues. J. Biomol. Screen., in press.
McEwen, 2013, Pharmacologic Characterization of a Kinetic In Vitro Human Co-culture Angiogenesis Model Using Clinically Relevant Compounds, J. Biomol. Screen., 18, 1234, 10.1177/1087057113502085
Guy, R. K. Eradicating BCR-ABL+ Acute Lymphoblastic Leukemia by Coadministering Dasatinib and Dihydroartemisinin. J. Biomol. Screen., in press.
Ellinger, B. A Phenotypic Screening Toolbox Permits the Identification of Novel Compounds with Anticancer Properties Derived from Marine Fungi. J. Biomol. Screen., in press.
Ludbrook, S. Development and Production of a Phenotypic Screening Approach in Cord Blood Derived Mast Cells to Identify Anti-Inflammatory Compounds. J. Biomol. Screen., in press.
Sanker, 2013, Development of High-Content Assays for Kidney Progenitor Cell Expansion in Transgenic Zebrafish, J. Biomol. Screen., 18, 1193, 10.1177/1087057113495296
Berg, 2013, Building Predictive Models for Target Mechanisms of Action from Phenotypic Assay Data Sets, J. Biomol. Screen., 18, 1260, 10.1177/1087057113505324
Azegrouz, 2013, Cell-Based Fuzzy Metrics Enhance High-Content Screening (HCS) Assay Robustness, J. Biomol. Screen., 18, 1270, 10.1177/1087057113501554
Reisen, 2013, Benchmarking of Multivariate Similarity Measures for High Content Screening Fingerprints in Phenotypic Drug Discovery, J. Biomol. Screen., 18, 1284, 10.1177/1087057113501390
Rappaz, B. Digital Holographic Microscopy: An Image-Based Label-Free Technology for Phenotypic Drug Discovery. J. Biomol. Screen., in press.